Table 5.
Logistic regression of demographic and clinical characteristics and the odds of obtaining a valid (resistant or susceptible) versus invalid (indeterminate) MTBDRplus v2 result
| Characteristics | Model 1 OR (95%CI) |
Model 2 OR (95%CI) |
Model 3 OR (95%CI) |
|---|---|---|---|
| Rifampicin Resistance | |||
|
| |||
| Smear gradation | |||
| Negative (ref) | |||
| Rare | 1.7 (0.9, 3.2) | 1.6 (0.9, 3.1) | 1.8 (0.9, 3.4) |
| Few | 6.0 (3.1, 11.4)* | 6.6 (3.0, 11.1)* | 6.6 (3.4, 12.7)* |
| Many | 11.8 (5.1, 27.0* | 11.6 (5.1, 26.7)* | 12.4 (5.4, 28.8)* |
| TNTC | 9.7 (5.3, 17.8)* | 8.9 (4.8, 16.6)* | 10.6 (5.6, 20.1)* |
| BMI | 0.9 (0.9, 1.0) | 0.9 (0.9, 1.0) | |
| Previously Treated | 0.6 (0.4, 1.1) | ||
| HIV status | 1.3 (0.7, 2.7) | ||
| Diabetic status | 0.7 (0.3, 1.7) | ||
|
| |||
| Isoniazid Resistance | |||
|
| |||
| Smear gradation | |||
| Negative (ref) | |||
| Rare | 1.6 (0.9, 3.0) | 1.6 (0.9, 3.0) | 1.7 (0.9, 3.2) |
| Few | 5.1 (2.9, 9.2)* | 5.1 (2.8, 9.1)* | 5.3 (2.9, 9.6)* |
| Many | 9.7(4.7, 20.0)* | 9.6 (4.7, 19.8)* | 10.0 (4.8, 20.6)* |
| TNTC | 10.3 (5.7, 18.4)* | 10.0 (5.5, 17.9)* | 10.6 (5.8, 19.5)* |
| BMI | 1.0 (0.9, 1.0) | 0.9 (0.9, 1.0) | |
| Previously Treated | 0.9 (0.5, 1.4) | ||
| HIV status | 1.3 (0.7, 2.5) | ||
| Diabetic status | 1.0 (0.4, 2.5) | ||
*
P values meeting significance criterion with an alpha < 0.05
OR= odds ratio; CI = confidence interval